Adalimumab (Humira) Biosimilar Well-Received By Patients Following US Launch
In January 2023, adalimumab-atto became the first biosimilar product available for the reference product adalimumab.
FDA Approves Ustekinumab-auub as Interchangeable Biosimilar to Stelara for Plaque Psoriasis, Psoriatic Arthritis, and More
The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.
Dermatology Pipeline Updates: Plaque Psoriasis, Atopic Dermatitis and More
The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics
Improving Adherence to Skin Self-Examination in High-Risk Individuals
Patient adherence to self-management strategies can be difficult.
Opioid Use in Psoriatic Arthritis Is Associated With Higher Health Care Costs, Utilization
New pathways of care are needed to improve health care spending.
Does CBD Play a Role in Acne Treatment?
CBD therapy has had positive outcomes in other inflammatory conditions.
WHO Declares Monkeypox a Global Health Emergency
The decision comes following reports of 16,000 cases across 75 countries and territories around the world.